Systemic sarcoidosis during pazopanib treatment for clear cell renal cell carcinoma

Indian J Dermatol Venereol Leprol. 2023 May-Jun;89(3):444-446. doi: 10.25259/IJDVL_599_2021.

Authors

Mario Vaccaro¹, Francesco Borgia¹, Maria Lentini², Michele Gaeta³, Ilenia MarafiotI¹

Affiliations

¹ Department of Clinical and Experimental Medicine, Dermatology, University of Messina, Messina, Italy.
² Department of Human Pathology, University of Messina, Messina, Italy.
³ Department of Biomedical, Dental Science and Morphological and Functional Images, Radiology Unit, University of Messina, Messina, Italy.

PMID: 36688889
DOI: 10.25259/IJDVL_599_2021

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Renal Cell* / diagnosis
Carcinoma, Renal Cell* / drug therapy
Humans
Indazoles
Kidney Neoplasms* / drug therapy
Pyrimidines / adverse effects
Sarcoidosis* / chemically induced
Sarcoidosis* / diagnosis
Treatment Outcome

Substances

pazopanib
Pyrimidines
Indazoles